Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2022 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profiles Than Existing Chemotherapy These NGC...